Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subjects aged 18 to 75 years, with Ulcerative Colitis in remission
You may not be if
Evidence of other forms of inflammatory bowel disease
Infectious disease (including human immunodeficiency virus \[HIV\], hepatitis B virus \[HBV\], or hepatitis C virus \[HCV\])
Disease limited to proctitis \<15 cm
Short bowel syndrome
Prior colon resection surgery
History of severe/fulminant UC
Intolerant or allergic to aspirin or salicylate derivatives
Use of rectal formulations (5-aminosalicylic acid \[5-ASA\], steroids) within ≤7 days
Women who are pregnant or nursing
History of known malignancy
History of bleeding disorders, active gastric or active duodenal ulcers, autoimmune diseases, or mental/ emotional disorders, that would interfere with their participation in the trial
Clareo Health | Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
